FDA Reduces Drug Approval Study Requirement
Analysis based on 7 articles · First reported Feb 18, 2026 · Last updated Feb 22, 2026
The market is expected to react positively to the United States===Food and Drug Administration's new policy, anticipating a surge in drug development and faster market entry for new medicines, particularly for common diseases. However, the differing approaches within the United States===Food and Drug Administration, as seen with Moderna's vaccine, may introduce some uncertainty for biotech companies.
The United States===Food and Drug Administration (FDA) plans to change its long-standing requirement for new drug approvals, moving from a default of two rigorous studies to one. This policy shift, announced by FDA Commissioner Marty Makary and deputy Vinay Prasad in the The New England Journal of Medicine, aims to accelerate drug development and availability by reducing bureaucracy. The FDA has historically required two studies to confirm results, but has increasingly accepted single studies for rare or fatal diseases since the 1990s. This new approach will primarily impact drugs for common diseases. Former FDA drug director Janet Woodcock supports the change, citing modern scientific advances. However, the FDA's vaccine division, also headed by Vinay Prasad, recently showed a more restrictive stance by initially refusing Moderna's mRNA flu shot application, highlighting potential inconsistencies in implementation.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard